Moderna, Inc. - Common Stock (MRNA)
44.07
-2.79 (-5.95%)
NASDAQ · Last Trade: Jan 30th, 4:43 PM EST
Detailed Quote
| Previous Close | 46.86 |
|---|---|
| Open | 45.98 |
| Bid | 44.00 |
| Ask | 44.04 |
| Day's Range | 43.43 - 46.34 |
| 52 Week Range | 22.28 - 55.20 |
| Volume | 10,935,810 |
| Market Cap | 17.23B |
| PE Ratio (TTM) | -5.461 |
| EPS (TTM) | -8.1 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 14,200,172 |
Chart
About Moderna, Inc. - Common Stock (MRNA)
Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More
News & Press Releases
Explore the top gainers and losers within the S&P500 index in today's session.chartmill.com
Via Chartmill · January 30, 2026
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer, beginning March 2, 2026. He will serve on Moderna's Executive Committee and report to Chief Executive Officer Stéphane Bancel. Dr. Jacqueline Miller will step down as Chief Medical Officer and member of the Executive Committee effective the same date and will remain as a consultant to the Company to assist with the transition.
Via ACCESS Newswire · January 30, 2026
Moderna will continue to lead clinical development and manufacturing for mRNA-3927
Via ACCESS Newswire · January 29, 2026
This forgotten pandemic stock hasn't said its last word.
Via The Motley Fool · January 28, 2026
Which S&P500 stocks have an unusual volume on Thursday?chartmill.com
Via Chartmill · January 22, 2026
MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now?stocktwits.com
Via Stocktwits · January 21, 2026
Monday's session: top gainers and losers in the S&P500 indexchartmill.com
Via Chartmill · January 26, 2026
Discover which S&P500 stocks are making waves on Monday.chartmill.com
Via Chartmill · January 26, 2026
As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the company is currently navigating the "Keytruda Cliff"—the 2028 expiration of patents for its $30 billion-a-year blockbuster. While Merck has spent the last five [...]
Via Finterra · January 26, 2026
What's going on in today's session: S&P500 gap up and gap down stockschartmill.com
Via Chartmill · January 26, 2026
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions.
While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.
Via StockStory · January 25, 2026
MarketBeat Week in Review – 01/19 - 01/23marketbeat.com
Via MarketBeat · January 24, 2026
Exploring the top movers within the S&P500 index during today's session.chartmill.com
Via Chartmill · January 23, 2026
Which S&P500 stocks are moving on Friday?chartmill.com
Via Chartmill · January 23, 2026
Friday's session: gap up and gap down stock in the S&P500 indexchartmill.com
Via Chartmill · January 23, 2026
Which S&P500 stocks are moving before the opening bell on Friday?chartmill.com
Via Chartmill · January 23, 2026
In a landmark moment for the future of personalized medicine, Moderna, Inc. (NASDAQ: MRNA) and Merck & Co., Inc. (NYSE: MRK) announced groundbreaking five-year follow-up data on January 20, 2026, for their experimental mRNA cancer vaccine. The results, stemming from the Phase 2b KEYNOTE-942 trial, demonstrated that the combination of Moderna’
Via MarketMinute · January 22, 2026
These S&P500 stocks are moving in today's sessionchartmill.com
Via Chartmill · January 22, 2026
Stay informed about the most active stocks in the S&P500 index on Thursday's session.chartmill.com
Via Chartmill · January 22, 2026
Top S&P500 movers in Thursday's sessionchartmill.com
Via Chartmill · January 22, 2026
As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based biotechnology giant is now aggressively shedding its image as a "one-hit wonder" vaccine maker. Following a volatile 2024 and 2025, the company has captured Wall [...]
Via Finterra · January 22, 2026
Moderna Inc (NASDAQ: MRNA) stock is trading higher Thursday morning, hitting a new 52-week high after new cancer trial data.
Via Benzinga · January 22, 2026
These S&P500 stocks are moving in today's pre-market sessionchartmill.com
Via Chartmill · January 22, 2026
The vaccine maker is expanding beyond its COVID-focused offerings.
Via The Motley Fool · January 21, 2026